When AI designs a drug, who gets the credit?

Biotech firm Insilico Medicine recently credited its generative AI platform for the discovery of a new drug candidate for pulmonary fibrosis. This claim has sparked a broader debate regarding intellectual property and the legal definition of an inventor when machine learning systems perform the primary design work. As pharmaceutical companies increasingly integrate AI into drug development, the industry faces mounting pressure to clarify whether AI-generated molecules qualify for traditional human-led patent protections.